Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open Label Study to Assess the Efficacy and Safety of the Intravenous and Oral Ibandronic Acid for Improving the Performance Status of Patients With Malignant Bone Disease Secondary to Solid Tumors and Hematological Malignancies.

Next Previous
X
Search
Trial Profile

A Randomized, Open Label Study to Assess the Efficacy and Safety of the Intravenous and Oral Ibandronic Acid for Improving the Performance Status of Patients With Malignant Bone Disease Secondary to Solid Tumors and Hematological Malignancies.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibandronic acid (Primary) ; Ibandronic acid (Primary)
  • Indications Bladder cancer; Cancer metastases; Gastrointestinal cancer; Haematological malignancies; Lung cancer; Multiple myeloma; Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Roche

    • Most Recent Events

    • 27 Sep 2015 New Source identified and integrated (ClinicalTrials.gov:NCT02561039).
    • 23 Mar 2008 Status changed from in progress to completed, from Roche record.
    • 20 Aug 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top